DLin-MC3-DMA

产品编号: DC10800 Featured
DLin-MC3-DMA
结构式
1224606-06-7
此产品仅供科研所需,我们不出售给病人
​我们将匹配市场上最好的价格给您
Email:order@dcbio.cn
免费咨询电话:4008862077
我们的合作伙伴:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
中国地区超过5000个高品质化合物库存
应用领域
D-Lin-MC3-DMA 是一种可离子化的氨基脂质类化合物, 是一种有效的递送 siRNA 载体。目前广泛应用于肿瘤基因治疗研究中。
Cas No.: 1224606-06-7
名称: O-(Z,Z,Z,Z-heptatriaconta-6,9,26,29-tetraen-19-yl)-4-(N,N-dimethylamino)
别名: D-Lin-MC3-DMA,DLinMC3DMA,D-Lin-MC-3-DMA,D-Lin-MC3-DMA
SMILES: CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC
分子式: C43H79NO2
分子量: 641.61
纯度: >98%
保存条件: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Technological advances in both siRNA (small interfering RNA) and whole genome sequencing have demonstrated great potential in translating genetic information into siRNA-based drugs to halt the synthesis of most disease-causing proteins. Despite its powerful promises as a drug, siRNA requires a sophisticated delivery vehicle because of its rapid degradation in the circulation, inefficient accumulation in target tissues and inability to cross cell membranes to access the cytoplasm where it functions. Lipid nanoparticle (LNP) containing ionizable amino lipids is the leading delivery technology for siRNA, with five products in clinical trials and more in the pipeline. Lipid nanoparticles (LNPs) formed by an ionizable cationic lipid (DLin-MC3-DMA), helper lipids (distearoylphosphatidylcholine, DSPC, and cholesterol), and a poly(ethylene glycol) (PEG) lipid have been identified as very promising delivery vectors of short interfering RNA (siRNA) in different clinical phases. DLin-MC3-DMA [14], which are 100-fold and 1000-fold more potent, respectively, in silencing of a hepatic gene (Factor VII) in comparison to the previous generation lipid DLin-DMA (1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane).The ED50 (median effective dose) for LNP containing DLin-MC3-DMA to silence Factor VII in mice and TTR in non-human primates was 0.005 mg/kg and 0.03 mg/kg, respectively. One of the key findings from these studies was the optimum lipid pKa value of 6.2–6.5 as a dominating factor in determining hepatic gene-silencing activity in vivo. DLin-MC3-DMA, having a pKa of 6.44, is currently the most active ionizable lipid being used in clinical trials.
In Vivo:
In Vitro:
References:
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
TITLE DOWNLOAD
MSDS_544_DC10800_1224606-06-7
COA
LOT NO. DOWNLOAD
产品编号 产品名称 应用领域
DC31024 Lipid 5 Lipid 5 is a novel ionizable lipid for RNA delivery.
DC31004 ATX-087 ATX-087 is a novel ionizable cationic lipids for RNA delivery.
DC31003 ATX-084 ATX-084 is an ionizable cationic lipids for RNA or Gene delivery.
DC31002 ATX-083 ATX-083 is an ionizable cationic lipids for RNA delivery.
DC31001 ATX-081 ATX-081 is an ionizable cationic lipids for RNA or Gene delivery.
DC12145 DLinDMA DLinDMA is a key lipid component of stable nucleic acid lipid particles as a benchmark.
DC10800 DLin-MC3-DMA D-Lin-MC3-DMA 是一种可离子化的氨基脂质类化合物, 是一种有效的递送 siRNA 载体。目前广泛应用于肿瘤基因治疗研究中。